Related Experiment Videos
Temporal Trends in Antineoplastic Agent-associated Interstitial Lung Disease Involving Immune Checkpoint Inhibitors
Yuki Ibayashi1, Hiroaki Watanabe2, Yusuke Shimura3
1Division of Pharmacy, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Background/Aim:
Cancer pharmacotherapy has advanced substantially with the introduction of novel agents such as immune checkpoint inhibitors (ICIs). However, managing drug-induced interstitial lung disease (DIILD) associated with these agents remains a major clinical challenge in maintaining treatment. Detailed investigations into recent changes in DIILD reporting and specific drug categories contributing to these changes remain limited. Therefore, we aimed to identify factors contributing to recent changes in DIILD reports by analyzing temporal trends in antineoplastic agent-associated DIILD using the Japanese Adverse Drug Event Report database.
Materials And Methods:
We analyzed the database reports from 2004 to 2024. The reporting odds ratio (ROR) and Weibull model were used to evaluate safety signals and the time to onset of ICI-associated DIILD, respectively.
Results:
The mean rate of antineoplastic agent-associated DIILD among total adverse event reports was significantly higher in the most recent period (2016-2024) than in the earlier period (2004-2015) (25.9% vs. 15.3%, p<0.05). An analysis by drug category suggested that an increase in ICI-associated reports from 2016 onward largely contributed to this upward trend. Significant signals were detected for ICI-associated DIILD (ROR for total reports: 4.13; ROR for reports with fatal outcomes: 2.73). Furthermore, there has been a shift towards combination therapy with ICIs and cytotoxic chemotherapy, accounting for the largest proportion of reports with fatal outcomes of ICI-associated DIILD in 2024. The Weibull analysis indicated an early failure pattern for ICI-associated DIILD.
Conclusion:
The recent increase in antineoplastic agent-associated DIILD may primarily be driven by the expanding use of ICIs, particularly ICI in combination with chemotherapy. Because DIILD tends to occur in the early phase of treatment, strict monitoring is warranted during the initial therapy period.
Insights
The incidence of drug-induced interstitial lung disease (DIILD) linked to cancer therapies has risen, driven by immune checkpoint inhibitors (ICIs). Early monitoring is crucial as DIILD often appears early in treatment, especially with combination therapies.
Area of Science:
- Oncology
- Pulmonology
- Pharmacovigilance
Background:
- Cancer pharmacotherapy has advanced with immune checkpoint inhibitors (ICIs).
- Managing drug-induced interstitial lung disease (DIILD) from these agents is challenging.
- Limited data exists on recent trends in DIILD reporting and contributing drug classes.
Purpose of the Study:
- To identify factors behind recent changes in DIILD reports.
- To analyze temporal trends in antineoplastic agent-associated DIILD.
- To investigate ICI-associated DIILD using the Japanese Adverse Drug Event Report database.
Main Methods:
- Analysis of Japanese Adverse Drug Event Report database (2004-2024).
- Utilized reporting odds ratio (ROR) for safety signal evaluation.
- Employed Weibull model to assess time to onset of ICI-associated DIILD.
Main Results:
- Antineoplastic agent-associated DIILD rates increased significantly from 2016-2024 compared to 2004-2015.
- Rising ICI use correlated with increased DIILD reports.
- Significant safety signals for ICI-associated DIILD were detected, with early onset patterns observed.
Conclusions:
- Increased antineoplastic agent-associated DIILD is linked to expanded ICI use, especially in combination therapy.
- DIILD commonly occurs early in treatment.
- Close monitoring during initial therapy is essential for managing ICI-associated DIILD.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
02:56Treatment Resistent Cancers